05:08 PM EDT, 08/13/2025 (MT Newswires) -- Verastem ( VSTM ) said Wednesday results from partner GenFleet Therapeutics' phase 1/2 trial in China of GFH375 in non-small cell lung cancer patients with a KRAS G12D mutation showed an overall response rate of 68.8% at a dose of 600 milligrams once a day.

Among the 26 patients with the disease treated across all dose levels, the overall response rate was 57.7%, the company said.

Verastem ( VSTM ) shares were rising 14.8% in recent after-hours activity.